Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the ...

The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process.

http://www.biospace.com/news_story.aspx?StoryID=280637&full=1